| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer
|
Lacouture, M.E.
|
|
|
27 |
9 |
p. 1712-1718
|
artikel
|
| 2 |
Cervical esophageal cancer: a gap in cancer knowledge
|
Hoeben, A.
|
|
|
27 |
9 |
p. 1664-1674
|
artikel
|
| 3 |
Challenging the soaring price of cancer medicines: a call for equity and transparency
|
Gonçalves, A.
|
|
|
27 |
9 |
p. 1812-1813
|
artikel
|
| 4 |
Communication in oncology: now we train - but how well? †
|
Stiefel, F.
|
|
|
27 |
9 |
p. 1660-1663
|
artikel
|
| 5 |
Editorial board
|
|
|
|
27 |
9 |
p. ii-iii
|
artikel
|
| 6 |
Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective study
|
Vardy, J.L.
|
|
|
27 |
9 |
p. 1761-1767
|
artikel
|
| 7 |
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches
|
Udager, A.M.
|
|
|
27 |
9 |
p. 1706-1712
|
artikel
|
| 8 |
Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma (ENKTL)
|
Tan, D.
|
|
|
27 |
9 |
p. 1811-1812
|
artikel
|
| 9 |
Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcome
|
Ruiz-Pinto, S.
|
|
|
27 |
9 |
p. 1788-1793
|
artikel
|
| 10 |
Inclusion of elderly patients in oncology clinical trials
|
Le Saux, O.
|
|
|
27 |
9 |
p. 1799-1804
|
artikel
|
| 11 |
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy
|
Ben-Ami, E.
|
|
|
27 |
9 |
p. 1794-1799
|
artikel
|
| 12 |
Long-term significance of urinary neopterin in ovarian cancer: a study by the Austrian Association for Gynecologic Oncology (AGO)
|
Volgger, B.M.
|
|
|
27 |
9 |
p. 1740-1746
|
artikel
|
| 13 |
New goals
|
Soria, J.-C.
|
|
|
27 |
9 |
p. 1655-1656
|
artikel
|
| 14 |
Oncolytic immunotherapy: an emerging new modality for the treatment of cancer
|
Coffin, R.S.
|
|
|
27 |
9 |
p. 1805-1808
|
artikel
|
| 15 |
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
|
Modest, D.P.
|
|
|
27 |
9 |
p. 1746-1753
|
artikel
|
| 16 |
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study
|
Delaloge, S.
|
|
|
27 |
9 |
p. 1725-1732
|
artikel
|
| 17 |
PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?
|
Al-Ahmadie, H.
|
|
|
27 |
9 |
p. 1658-1659
|
artikel
|
| 18 |
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma †
|
Simonelli, M.
|
|
|
27 |
9 |
p. 1782-1787
|
artikel
|
| 19 |
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
|
Trillsch, F.
|
|
|
27 |
9 |
p. 1733-1739
|
artikel
|
| 20 |
Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries
|
Kleijnen, S.
|
|
|
27 |
9 |
p. 1768-1775
|
artikel
|
| 21 |
Reply to ‘Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients’ by C. Cremolini et al.
|
Luo, H.Y.
|
|
|
27 |
9 |
p. 1810-1811
|
artikel
|
| 22 |
Reply to ‘The challenge to one course carboplatin in seminoma clinical stage 1’ by Dieckmann and Anheuser
|
Tandstad, T.
|
|
|
27 |
9 |
p. 1809
|
artikel
|
| 23 |
Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)
|
Jerusalem, G.
|
|
|
27 |
9 |
p. 1719-1725
|
artikel
|
| 24 |
Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients
|
Cremolini, C.
|
|
|
27 |
9 |
p. 1810
|
artikel
|
| 25 |
Saving the best treatment for last?
|
Coleman, R.L.
|
|
|
27 |
9 |
p. 1656-1658
|
artikel
|
| 26 |
Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective
|
Shenoy, N.
|
|
|
27 |
9 |
p. 1685-1695
|
artikel
|
| 27 |
Stepped care targeting psychological distress in head and neck cancer and lung cancer patients: a randomized, controlled trial
|
Krebber, A.M.H.
|
|
|
27 |
9 |
p. 1754-1760
|
artikel
|
| 28 |
Successful treatment of refractory leiomyosarcoma with the PD-1 inhibitor nivolumab
|
Heine, A.
|
|
|
27 |
9 |
p. 1813-1814
|
artikel
|
| 29 |
Table of Contents
|
|
|
|
27 |
9 |
p. iv-v
|
artikel
|
| 30 |
The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy
|
Clancy, A.A.
|
|
|
27 |
9 |
p. 1696-1705
|
artikel
|
| 31 |
The promise of immunotherapy in head and neck squamous cell carcinoma
|
Economopoulou, P.
|
|
|
27 |
9 |
p. 1675-1685
|
artikel
|
| 32 |
To be in pain (or not): a computer enables outpatients to inform their physician
|
Oldenmenger, W.H.
|
|
|
27 |
9 |
p. 1776-1781
|
artikel
|
Tijdschrift beschrijving